INDIA STOCKS-Indian shares set to open lower ahead of RBI rate decision - Yahoo Finance
| RASP Stock | USD 0 0.00 0.00% |
Slightly above 56% of Rasna Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Rasna Therapeutics pink sheet suggests that many investors are alarmed at this time. Rasna Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Rasna Therapeutics. Many technical investors use Rasna Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Rasna |
INDIA STOCKS-Indian shares set to open lower ahead of RBI rate decision Yahoo Finance
Read at news.google.com
 |
Rasna Therapeutics Fundamental Analysis
We analyze Rasna Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rasna Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rasna Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
Rasna Therapeutics is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Rasna Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Rasna Therapeutics pink sheet to make a market-neutral strategy. Peer analysis of Rasna Therapeutics could also be used in its relative valuation, which is a method of valuing Rasna Therapeutics by comparing valuation metrics with similar companies.
Peers
Rasna Therapeutics Related Equities
| ACUT | Accustem Sciences | 4.17 | ||||
| VTYX | Ventyx Biosciences | 1.34 | ||||
| GHRS | GH Research | 1.29 | ||||
| BNOX | Bionomics | 1.24 | ||||
| IMCR | Immunocore Holdings | 1.16 | ||||
| ACLX | Arcellx | 1.03 | ||||
| PCVX | Vaxcyte | 1.34 | ||||
| IGC | India Globalization | 2.76 | ||||
| SPRC | Scisparc | 3.83 | ||||
| SABS | SAB Biotherapeutics | 4.21 |
Additional Tools for Rasna Pink Sheet Analysis
When running Rasna Therapeutics' price analysis, check to measure Rasna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rasna Therapeutics is operating at the current time. Most of Rasna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rasna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rasna Therapeutics' price. Additionally, you may evaluate how the addition of Rasna Therapeutics to your portfolios can decrease your overall portfolio volatility.